As GLP-1R agonists have been shown in several large-scale trials to improve cardiovascular outcomes in people with T2D [107], while also stimulating cardiac glucose oxidation in preclinical studies [58,130], they may represent a more feasible approach to modifying cardiac glucose metabolism. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.